298 patents
Page 4 of 15
Utility
Ruxolitinib for the Treatment of Prurigo Nodularis
3 Nov 22
This disclosure relates to ruxolitinib, or a pharmaceutically acceptable salt thereof, and its use in treating prurigo nodularis.
Paul Smith, Jörg Wenzel
Filed: 3 May 22
Utility
Heterocyclic Compounds As Immunomodulators
3 Nov 22
Liangxing Wu, Kaijiong Xiao, Wenqing Yao
Filed: 24 Jun 22
Utility
Substituted Heterocyclic Derivatives As PI3K Inhibitors
27 Oct 22
Stacey Shepard, Andrew P. Combs
Filed: 22 Jun 22
Utility
Pyrazolyl Bicyclic Amines As CDK2 Inhibitors
27 Oct 22
Joshua Hummel, David M. Burns, Liangxing Wu, Wenqing Yao
Filed: 12 Apr 22
Utility
PYRIDO[3,2-D]PYRIMIDINE Compounds As Immunomodulators
27 Oct 22
Jingwei Li, Liangxing Wu, Wenqing Yao
Filed: 27 Jun 22
Utility
Sustained-release Dosage Forms of Ruxolitinib
20 Oct 22
The present invention relates to sustained-release formulations and dosage forms of ruxolitinib, or a pharmaceutically acceptable salt thereof, which are useful in the treatment of Janus kinase-associated diseases such as myeloproliferative disorders.
Yong Ni, Bhavnish Parikh, Krishnaswamy Yeleswaram, Susan Erickson-Viitanen, William V. Williams
Filed: 23 Jun 22
Utility
1,2,5-Oxadiazoles As Inhibitors Of Indoleamine 2,3- Dioxygenase
20 Oct 22
The present invention is directed to 1,2,5-oxadiazole derivatives, and compositions of the same, which are inhibitors of indoleamine 2,3-dioxygenase and are useful in the treatment of cancer and other disorders, and to the processes and intermediates for making such 1,2,5-oxadiazole derivatives.
Andrew P. Combs, Eddy W. Yue, Richard B. Sparks, Wenyu Zhu, Jiacheng Zhou, Qiyan Lin, Lingkai Weng, Tai-Yuen Yue, Pingli Liu
Filed: 16 Nov 21
Utility
JAK1 Pathway Inhibitors for the Treatment of Chronic Lung Allograft Dysfunction
20 Oct 22
This disclosure relates to JAK1 pathway inhibitors and the use thereof in treating chronic lung allograft dysfunction such as, e.g., bronchiolitis obliterans syndrome.
Richard L. Schaub, Kevin O`Hayer
Filed: 30 Jun 22
Utility
Sustained-release Dosage Forms of Ruxolitinib
13 Oct 22
The present invention relates to sustained-release formulations and dosage forms of ruxolitinib, or a pharmaceutically acceptable salt thereof, which are useful in the treatment of Janus kinase-associated diseases such as myeloproliferative disorders.
Yong Ni, Bhavnish Parikh, Krishnaswamy Yeleswaram, Susan Erickson-Viitanen, William V. Williams
Filed: 23 Jun 22
Utility
Combination Therapy Comprising an FGFR Inhibitor and a NECTIN-4 Targeting Agent
13 Oct 22
The present disclosure relates to methods of treating cancer by administering a compound, which is an Fibroblast Growth Factor Receptor (FGFR) inhibitor, in combination with enfortumab vedotin.
Holly K. Koblish, Rodrigo Hess
Filed: 11 Apr 22
Utility
Imidazopyridazine and Imidazopyridine Compounds and Uses Thereof
6 Oct 22
Jun Pan, Jeremy Roach, Song Mei, Chunhong He, Liangxing Wu, Wenqing Yao
Filed: 9 Jun 22
Utility
Crystalline Solid Forms of a Bet Inhibitor
29 Sep 22
The present application relates to crystalline solid forms of an inhibitor of BET proteins such as BRD2, BRD3, BRD4, and BRD-t, including methods of preparation thereof, and intermediates in the preparation thereof, where the compound is useful in the treatment of diseases such as cancer.
Shili Chen, Zhongjiang Jia, Pingli Liu, Lei Qiao, Yongzhong Wu, Jiacheng Zhou, Qun Li
Filed: 2 Jun 22
Utility
Imidazole and Triazole Kras Inhibitors
29 Sep 22
Chao Qi, Xiaozhao Wang, Wenqing Yao
Filed: 22 Mar 22
Utility
Salts of the Janus Kinase Inhibitor (R)-3-(4-(7h-Pyrrolo[2,3-D]Pyrimidin-4-YL)-1h-Pyrazol-1-Yl)-3- Cyclopentylpropanenitrile
15 Sep 22
The present invention provides salt forms of (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile that are useful in the modulation of Janus kinase activity and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases.
Hui-Yin Li, James D. Rodgers
Filed: 29 Nov 21
Utility
Ruxolitinib Formulation for Reduction of Itch In Atopic Dermatitis
8 Sep 22
This disclosure relates to methods of reducing itch in patients with atopic dermatitis and treating patients with atopic dermatitis by administering a topical 0.75% or 1.5% ruxolitinib cream two times per day.
Michael Kuligowski, Kang Sun, Michael Howell, May Grace E. Venturanza, Jim Lee
Filed: 28 Mar 22
Utility
Spirocyclic Lactams As JAK2 V617F Inhibitors
8 Sep 22
The present application provides spirocyclic lactam compounds that modulate the activity of the V617F variant of JAK2, which are useful in the treatment of various diseases, including cancer.
Stacey Shepard, Charles Cole, Nikoo Falahatpisheh, Kai Liu, Lixin Shao, Darius Vrubliauskas, Liangxing Wu, Wenqing Yao, Eddy W. Yue
Filed: 24 Feb 22
Utility
Formulations of an Axl/mer Inhibitor
1 Sep 22
The present application relates to pharmaceutical formulations and dosage forms of an AXL/MER inhibitor, or a pharmaceutically acceptable salt, solvate, or hydrate thereof, including methods of preparation thereof, which are useful in the treatment of AXL/MER mediated diseases such as cancer.
William L. Rocco, Francis X. Muller
Filed: 28 Dec 21
Utility
HETEROCYCLIC COMPOUNDS AS PI3K-y INHIBITORS
11 Aug 22
Andrew W. Buesking, Richard B. Sparks, Andrew P. Combs, Brent Douty, Nikoo Falahatpisheh, Lixin Shao, Stacey Shepard, Eddy W. Yue, Artem Shvartsbart, David M. Burns, Daniel Levy
Filed: 23 Feb 21
Utility
Treatment of Hidradenitis Suppurativa Using Jak Inhibitors
4 Aug 22
The present application provides methods of treating hidradenitis suppurativa in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a compound which inhibits JAK1 and/or JAK2, or a pharmaceutically acceptable salt thereof.
Michael D. Howell, Paul Smith
Filed: 13 Apr 22
Utility
Combination Therapy with an ANTI-CD19 Antibody and Parsaclisib
4 Aug 22
The present disclosure describes a combination of an anti-CD19 antibody and parsaclisib for the treatment of non-Hodgkin lymphoma, chronic lymphocytic leukemia, and acute lymphoblastic leukemia.
Peter Langmuir
Filed: 30 Nov 21